Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28074397 | 0.79 | CYP2D6 (0.40) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL18763458 | 0.74 | — | — | |
| SCHEMBL11256813 | 0.73 | — | — | |
| SCHEMBL11272440 | 0.72 | — | — | |
| SCHEMBL27881959 | 0.71 | — | — | |
| SCHEMBL15415280 | 0.71 | — | — | |
| SCHEMBL20521142 | 0.64 | — | — | |
| SCHEMBL18763492 | 0.64 | HRH4 (0.36) | — | |
| SCHEMBL15747950 | 0.63 | MEN1 (0.46) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL938780 | 0.58 | MEN1 (0.65) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020025947-A1 | Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2002-02-28 | — | — | US | claimed |
| US-6660885-B2 | Serine protease inhibitor | PHARMACIA CORPORATION | 2003-12-09 | — | — | US | disclosed |
| US-20020025947-A1 | Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025947-A1 | Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade | TFPI, TFPI2, PLAT | MEN1 3795/4885CYP2D6 954/4885CYP2C19 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.